Exane Derivatives’s Jazz Pharmaceuticals JAZZ Stock Holding History

Exane Derivatives’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-20	Closed	-$3.11K	–	867
2022 Q1	$3.11K	Hold	20	–	–	﹤0.01%	727
2021 Q4	$2.55K	Hold	20	–	–	﹤0.01%	649
2021 Q3	$2.6K	Hold	20	–	–	﹤0.01%	785
2021 Q2	$3.65K	Buy	20 +16	+400%	+$2.77K	﹤0.01%	789
2021 Q1	$658	Hold	4	–	–	﹤0.01%	769
2020 Q4	$660	Hold	4	–	–	﹤0.01%	712
2020 Q3	$570	Hold	4	–	–	﹤0.01%	665
2020 Q2	$441	Hold	4	–	–	﹤0.01%	622
2020 Q1	$399	Hold	4	–	–	﹤0.01%	621
2019 Q4	$611	Buy	+4	New	+$544	﹤0.01%	595

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

Exane Derivatives's JAZZ Position: Q2 2022 in Review

Exane Derivatives sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2022, closing a stake of 20 shares — an estimated $3.11K sold.

Exane Derivatives first reported a position in JAZZ in Q4 2019 and held it in 10 quarters. The position peaked at $3.65K in Q2 2021. 468 funds tracked by Wall St. Rank hold JAZZ as of Q2 2022.

Exane Derivatives reported no remaining Jazz Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Exane Derivatives sold 20 Jazz Pharmaceuticals shares in Q2 2022, an estimated $3.11K.
Exane Derivatives first reported a position in Jazz Pharmaceuticals in Q4 2019 and held it in 10 quarters.
Exane Derivatives's Jazz Pharmaceuticals position peaked at $3.65K in Q2 2021.
468 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.